We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, today announced the appointment of Charles (Chuck) ...

Shares of AbbVie Inc. ABBV slipped 0.74% to $174.37 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6,084.19 and ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies, today announced significant progress in its ...

The global nanotechnology drug delivery market, valued at US$ 77.1 billion in 2020, is projected to grow at a compound annual ...

AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what ...

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

Google stock hit a new high on Dec. 11 clearing a entry point amid a new quantum-computing chip and the unveiling of Gemini 2 ...

GE Aerospace hiked its dividend 250% in April; GE HealthCare raised its 17% in November; and GE Vernova just initiated a ...